已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia

阿糖胞苷 医学 米托蒽醌 内科学 随机对照试验 危险系数 胃肠病学 白血病 化疗 外科 置信区间 肿瘤科
作者
Hui Wei,Ying Wang,Robert Peter Gale,Dong Lin,Chunlin Zhou,Bingcheng Liu,Shaowei Qiu,Runxia Gu,Yan Li,Xingli Zhao,Shuning Wei,Benfa Gong,Kaiqi Liu,Xiaoyuan Gong,Yuntao Liu,Guangji Zhang,Zhen Song,Yang Wang,Wei Li,Yingchang Mi
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:26 (13): 3154-3161 被引量:42
标识
DOI:10.1158/1078-0432.ccr-19-3433
摘要

Abstract Purpose: Cytarabine, 100–200 mg/mE+2/day, is commonly used in induction therapy of acute myelogenous leukemia (AML). Whether a higher dose of cytarabine would be more effective is unknown. Also, there is controversy whether high-dose cytarabine is better than an intermediate-dose combined with other drugs for post-remission therapy. In this open-label, randomized controlled, parallel group study, roles of intermediate-dose cytarabine were investigated. Patients and Methods: Subjects with AML age 15–55 years were randomized to receive daunorubicin, omacetaxine mepesuccinate, and conventional- or intermediate-dose cytarabine. Subjects achieving complete remission were randomized to receive 3 courses of high-dose cytarabine or 2 courses of intermediate-dose cytarabine with daunorubicin in the 1st and mitoxantrone in the 2nd course. The primary endpoint was disease-free survival (DFS). Results: 591 subjects were randomized to intermediate- (N = 295) or conventional-dose (N = 296) cytarabine group. Three-year DFSs were 67% [95% confidence interval (CI), 61–73] in the intermediate-dose cohort compared with 54% (95% CI, 48–61) in the conventional-dose cohort [Hazard Ratio (HR), 0.67; 95%CI, 0.51–0.89; P = 0.005). Three-year survivals were 68% (95%CI, 63–74) and 59% (95%CI, 53–65; HR, 0.720; 95%CI, 0.56–0.94; P = 0.014). Two courses of intermediate-dose cytarabine with daunorubicin or mitoxantrone resulted in similar DFS and survival as three courses of high-dose cytarabine when used for post-remission therapy. Conclusions: Induction therapy with intermediate-dose cytarabine with daunorubicin and omacetaxine mepesuccinate increases DFS and survival in persons with AML ages 15–55 years compared with conventional-dose cytarabine. See related commentary by Watts and Bradley, p. 3073
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
好久不见发布了新的文献求助10
2秒前
4秒前
玉洁松贞的应助被阿苏采纳,获得30
4秒前
4秒前
5秒前
科研通AI6.2的应助被高大橙采纳,获得10
6秒前
huifeideyu发布了新的文献求助10
6秒前
6秒前
window1000发布了新的文献求助10
6秒前
7秒前
9秒前
archon709发布了新的文献求助10
9秒前
11秒前
vc发布了新的文献求助10
11秒前
11秒前
11秒前
11秒前
小鱼发布了新的文献求助10
11秒前
13秒前
13秒前
14秒前
陈俊涛发布了新的文献求助20
15秒前
15秒前
栗子发布了新的文献求助10
16秒前
17秒前
disappear发布了新的文献求助10
18秒前
xiaohan发布了新的文献求助10
18秒前
Zinco1027发布了新的文献求助10
18秒前
Akim的应助被泽佑采纳,获得10
18秒前
18秒前
科目三的应助被困了采纳,获得10
20秒前
玲玲发布了新的文献求助10
20秒前
Lee完成签到,获得积分10
22秒前
树123发布了新的文献求助10
22秒前
Crssss的应助被哈基米大魔王采纳,获得10
23秒前
酷波er的应助被舒心的思山采纳,获得10
23秒前
甜甜玉米完成签到 ,获得积分10
24秒前
edisonzz发布了新的文献求助10
24秒前
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179198
求助须知:如何正确求助?哪些是违规求助? 9569781
关于积分的说明 21806509
捐赠科研通 7774542
什么是DOI,文献DOI怎么找? 3433008
关于科研通互助平台的介绍 2556929
邀请新用户注册赠送积分活动 2478652